The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 120 participants will be randomized.

The study involves gathering information via one-on-one patient interviews, surveys and questionnaires so that we can better understand the patient decision-making process involved in bladder cancer treatment.

Create a living biobank of PDOs from Stage I-III lung cancer patients.